- Home
- IPHA vs NPWR Comparison
IPHA vs NPWR Comparison
Compare IPHA & NPWR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IPHA
- NPWR
- Stock Information
- Founded
- IPHA 1999
- NPWR 2010
- Country
- IPHA France
- NPWR United States
- Employees
- IPHA N/A
- NPWR N/A
- Industry
- IPHA Biotechnology: Pharmaceutical Preparations
- NPWR Industrial Machinery/Components
- Sector
- IPHA Health Care
- NPWR Energy
- Exchange
- IPHA Nasdaq
- NPWR Nasdaq
- Market Cap
- IPHA 160.1M
- NPWR 148.7M
- IPO Year
- IPHA 2019
- NPWR N/A
- Fundamental
- Price
- IPHA $1.83
- NPWR $2.16
- Analyst Decision
- IPHA Strong Buy
- NPWR Buy
- Analyst Count
- IPHA 1
- NPWR 2
- Target Price
- IPHA $11.00
- NPWR $4.00
- AVG Volume (30 Days)
- IPHA 10.0K
- NPWR 2.7M
- Earning Date
- IPHA 03-27-2025
- NPWR 08-11-2025
- Dividend Yield
- IPHA N/A
- NPWR N/A
- EPS Growth
- IPHA N/A
- NPWR N/A
- EPS
- IPHA N/A
- NPWR N/A
- Revenue
- IPHA $20,831,349.00
- NPWR $250,000.00
- Revenue This Year
- IPHA $209.83
- NPWR $308.00
- Revenue Next Year
- IPHA $83.15
- NPWR $1,811.08
- P/E Ratio
- IPHA N/A
- NPWR N/A
- Revenue Growth
- IPHA N/A
- NPWR 100.00
- 52 Week Low
- IPHA $1.29
- NPWR $1.48
- 52 Week High
- IPHA $3.51
- NPWR $14.28
- Technical
- Relative Strength Index (RSI)
- IPHA 33.33
- NPWR 47.55
- Support Level
- IPHA $1.82
- NPWR $2.30
- Resistance Level
- IPHA $2.21
- NPWR $2.63
- Average True Range (ATR)
- IPHA 0.07
- NPWR 0.38
- MACD
- IPHA -0.03
- NPWR -0.02
- Stochastic Oscillator
- IPHA 6.74
- NPWR 22.48
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.
About NPWR NET Power Inc.
NET Power Inc is a clean energy technology company that has developed a novel power generation system, which it refers to as the NET Power Cycle, designed to produce clean, reliable, and low-cost electricity from natural gas while capturing virtually all atmospheric emissions. The company's business model is to license its technology to customers and enable them to build, own, and operate facilities that utilize the Net Power Cycle. It has conducted a successful demonstration of its technology at the La Porte Demonstration Facility and is developing a utility-scale power plant in Texas named Project Permian.